Common side effects of tirzepatide and semaglutide include nausea, vomiting, and diarrhea, but tirzepatide may have a more favorable gastrointestinal tolerability profile
Food and Drug Administration in 2017, semaglutide is sold as Ozempic to treat diabetes and as Wegovy for weight loss
Reporting side effects to healthcare providers is critical
Tirzepatide combines GLP-1 and GIP receptor activation
Most protocols deliver 1 to 3 mg per day subcutaneously, either daily or 5 days on with 2 days off
By reducing appetite, slowing gastric emptying, enhancing insulin secretion, and inhibiting glucagon release, it helps individuals achieve and maintain meaningful weight loss